Panacea Biotec Ltd. (NSE: PANACEABIO, BSE: 531349) is a New Delhi, Delhi-based company in the Vaccines and Biologics industry. With a market capitalisation of ₹2,166 Cr, it ranks #1,206 by market cap among the 6,197 Indian listed companies on FinBizNet, and #1 of 2 in Vaccines and Biologics. At ₹359.90 (as of 16 Nov 2026), the share price is 44.4% below its 52-week high of ₹647.00 and 23.1% above its 52-week low of ₹292.40. The share price is down 14.5% over one year and down 14.4% over three months.
| Current Price | ₹359.90 |
|---|---|
| Market Cap | ₹2,166 Cr |
| NSE Symbol | PANACEABIO |
| BSE Code | 531349 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Biotechnology |
| Sub-Industry | Biotechnology > Vaccines and Biologics |
| P/E Ratio | Not meaningful (loss) |
| Return on Equity | -0.86% |
| Return on Assets | -1.32% |
| 52-Week Range | ₹292.40 – ₹647.00 |
| 1-Year Price Change | -14.5% |
| 3-Month Price Change | -14.4% |
| Beta (1Y) | 0.17 |
| Dividend Yield | 0.00% |
| Headquarters | New Delhi, Delhi |
| Website | www.panaceabiotec.com |
| Revenue | ₹190 Cr |
|---|---|
| Net Profit | ₹12 Cr |
| Net Margin | 6.3% |
| EPS (Basic) | ₹1.90 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Panacea Biotec Ltd. reported revenue of ₹190 Cr in Q2 FY27, up 34.4% from ₹141 Cr in Q2 FY26 and down 5.0% from ₹200 Cr in Q1 FY27. It posted a net profit of ₹12 Cr for the quarter, against a net loss of ₹14 Cr in Q2 FY26. Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹133 Cr (Q4 FY25) to ₹200 Cr (Q1 FY27). The company reported a net loss in 3 of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹190 Cr | ₹12 Cr | 6.3% |
| Q1 FY27 | ₹200 Cr | ₹2 Cr | 1.1% |
| Q4 FY26 | ₹167 Cr | −₹1 Cr | −0.6% |
| Q3 FY26 | ₹165 Cr | ₹4 Cr | 2.4% |
| Q2 FY26 | ₹141 Cr | −₹14 Cr | −9.9% |
| Q1 FY26 | ₹167 Cr | ₹4 Cr | 2.4% |
| Q4 FY25 | ₹133 Cr | −₹2 Cr | −1.5% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 72.48% of Panacea Biotec Ltd.'s shares as of Sept 2026, unchanged from Sept 2025. Delivery averaged 51.9% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Panacea Biotec Limited, a biotechnology company, engages in the research, development, manufacture, and marketing of vaccines, pharmaceutical formulations, nutraceuticals, and food and nutrition products in India and internationally. It operates through Vaccines and Pharmaceutical formulations & Nutrition segments. The company’s product portfolio includes prescription products in various therapeutic areas, such as oncology, diabetes, gastro-intestinal care, nephrology, orthopedics, pain management, and fever; cold and cough; and betacoronavirus, SARS-CoV-2, typhoid conjugate, pneumococcal conjugate, tetravalent dengue, Mpox, and hepatitis A vaccines etc. It also offers health supplement products; and paediatric nutrition products under the ChilRunFull, ChilRun 7+, and ChillRun No Sucrose brands. In addition, the company engages in the real estate business. It exports its products to approximately 50 countries. The company has collaboration agreements with the Russian Direct Investment
1. Vaccines-This segment researches, develops, manufactures, and markets vaccines. 2. Formulations-This segment researches, develops, manufactures, and markets pharmaceutical formulations. 3. Vaccines - Discontinued Operations-This segment researches, develops, manufactures, and markets vaccines. 4. Real Estate - Discontinued Operations-This segment engages in the real estate business.
1. Vaccines-64.1% 2. Pharmaceutical Formulations & Nutrition-35.9%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Panacea Biotec Ltd. | ₹2,166 Cr | n/m | -0.86% | ₹190 Cr | -14.5% |
| Bharat Immunologicals & Biologics Ltd | ₹39 Cr | n/m | -17.19% | ₹0 Cr | -29.7% |
Listed by market capitalisation. Ratios are shown for context only.
Panacea Biotec Ltd. is trading at ₹359.90, with a market capitalisation of ₹2,166 Cr.
Panacea Biotec Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Biotechnology space (Biotechnology > Vaccines and Biologics).
Panacea Biotec Ltd. has a return on equity of -0.86%.
Panacea Biotec Ltd. is listed on the NSE under the symbol PANACEABIO and on the BSE under the scrip code 531349.
Panacea Biotec Ltd.'s share price is down 14.5% over one year and down 14.4% over three months. Its 52-week range is ₹292.40 to ₹647.00.
In Q2 FY27, Panacea Biotec Ltd. reported revenue of ₹190 Cr and net profit of ₹12 Cr, with basic EPS of ₹1.9 (consolidated, parsed from the company's exchange filing).
Panacea Biotec Ltd. reported revenue of ₹190 Cr in Q2 FY27, up 34.4% from ₹141 Cr in Q2 FY26 and down 5.0% from ₹200 Cr in Q1 FY27.
Promoters held 72.48% of Panacea Biotec Ltd.'s shares as of Sept 2026, unchanged from Sept 2025.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.